País: Nueva Zelanda
Idioma: inglés
Fuente: Medsafe (Medicines Safety Authority)
Adenosine 3 mg/mL; ;
Baxter Healthcare Ltd
Adenosine 3 mg/mL
6 mg/2mL
Solution for injection
Active: Adenosine 3 mg/mL Excipient: Sodium chloride Water for injection
Prescription
Xinxiang Tuoxin Biochemical Technology & Science Co Ltd
Therapeutic Indications Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White syndrome). Diagnostic Indications Aid to diagnosis of broad or narrow QRS complex supraventricular tachycardias. Although Adenosine-Claris 6 mg/2 ml is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity. Sensitisation of intra-cavitary electrophysiological investigations.
Package - Contents - Shelf Life: Vial, glass, sulfur-treated Ph Eur type I clear 2 mL with teflon-coated rubber stopper - 5 dose units - 24 months from date of manufacture stored at or below 30°C. Do not refrigerate - Vial, glass, sulfur-treated Ph Eur type I clear 2 mL with teflon-coated rubber stopper - 10 dose units - 24 months from date of manufacture stored at or below 30°C. Do not refrigerate - Vial, glass, sulfur-treated Ph Eur type I clear 2 mL with teflon-coated rubber stopper - 25 dose units - 24 months from date of manufacture stored at or below 30°C. Do not refrigerate
2016-12-19
NEW ZEALAND DATA SHEET ADSINE Data Sheet 8 November 2022 Page 1 of 8 Baxter Healthcare Ltd 1 ADSINE (6mg/2mL, solution for injection) ADSINE 6mg/2mL solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION _ACTIVE INGREDIENT _ ADSINE solution for injection contains 6mg/2mL adenosine (equivalent to 3mg/mL). For the full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to almost colourless solution essentially free from visible particles. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff ‐ Parkinson ‐ White syndrome). _DIAGNOSTIC INDICATIONS _ Aid to diagnosis of broad or narrow QRS complex supraventricular tachycardias. Although ADSINE 6mg/2mL is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity. Sensitisation of intra-cavitary electrophysiological investigations. 4.2 Dose and method of administration ADSINE 6mg/2mL should be used only in hospitals, with monitoring and cardiorespiratory resuscitation equipment available for immediate use if necessary. It should be administered by rapid IV bolus injection according to the ascending dosage schedule below. To be certain the solution reaches the systemic circulation, it should be administered either directly into a vein or into an IV line. If administered via an IV line it should be injected as proximally as possible, and followed by a rapid saline flush. ADSINE 6mg/2mL should only be used when facilities exist for cardiac monitoring. Patients who develop high ‐ level AV block at a particular dose should not be given further dosage increments. _THERAPEUTIC DOSE _ _Adults _ _Initial dose:_ 3mg given as a rapid intravenous bolus (over 2 seconds). _Second dose:_ If the first dose does not result in the elimination of supraventricular tac Leer el documento completo